Search Results for: 43

— Initiated Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection and Antibiotic Associated Diarrhea — — Initiated Second Phase 2 Clinical Trial to Evaluate the Sustainability of Reduced Methane Production in Patients with Irritable Bowel Syndrome with Constipation — — Conference Call Today, November 5, 2015, at 4:30 p.m. EST — […]

— Conference Call Scheduled for Thursday, November 5, 2015 at 4:30 p.m. EST — ROCKVILLE, Md., Oct. 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its financial results for the three and nine months ended September

— Trial to Evaluate the Ability of SYN-010 to Sustain the Reduction of Methane Production in the Gut for Patients who have Completed First Phase 2 Clinical Trial of SYN-010 — — Methane Production is Perceived as the Underlying Cause of Pain, Bloating and Constipation Associated with IBS-C — ROCKVILLE, Md., Oct. 8, 2015 /PRNewswire/

ROCKVILLE, Md., July 16, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced that it has priced an underwritten public offering of 13.3 million shares of common stock at a price of $3.00 per share, for expected gross proceeds

ROCKVILLE, Md., March 2, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that preclinical results supporting the development of SYN-005 for the treatment of Pertussis will be highlighted at ECCMID 2015 (European Congress of Clinical Microbiology

— Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics’ C-IBS Clinical Advisory Board — ROCKVILLE, Md., Sept. 10, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases,

— Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C. difficile and C-IBS Programs into the Clinic During 2014 — — Conference Call Today, August 14, 2014, at 8:30 a.m. (EDT); U.S. Participants Call (877) 870-4263 or Join Webcast at http://www.videonewswire.com/event.asp?id=100224 — ROCKVILLE, Md., Aug. 14,

— Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics’ C-IBS Clinical Advisory Board — ROCKVILLE, Md., Aug. 13, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and

— Conference Call Today, May 15, 2014, at 8:30 a.m. (EDT) — ROCKVILLE, Md., May 15, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three months ended March 31, 2014, and

— Progress Cited On Three Infectious Disease Programs, Including Two Programs in Collaboration with Intrexon Corporation; C. difficile Prophylactic is Lead Anti-Infective Candidate — ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for